Spots Global Cancer Trial Database for lymphoma
Every month we try and update this database with for lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma | NCT05446688 | Lymphoma | 6MW3211 | 18 Years - | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | NCT03099031 | Venous Thromboe... | Tinzaparin | 18 Years - | LEO Pharma | |
| Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma | NCT00005959 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - | National Cancer Institute (NCI) | |
| Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma | NCT04797182 | Thrombocytopeni... Cytarabine Caus... Lymphoma | avatrombopag | 18 Years - 70 Years | Sun Yat-sen University | |
| Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | NCT00450385 | Lymphoma | Rituximab Cyclophosphamid... Doxorubicin Prednisone Vincristine | 18 Years - 120 Years | University of Miami | |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | NCT03205176 | Malignant Solid... Lymphoma Ovarian Cancer Breast Cancer Pancreatic Canc... Prostate Cancer | AZD5153 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00090909 | Lymphoma | cisplatin dexamethasone gemcitabine hyd... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | NCT00055640 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... microarray anal... | 18 Years - | Case Comprehensive Cancer Center | |
| An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | NCT02808780 | Ulcerative Coli... | 18 Years - | Janssen Biotech, Inc. | ||
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | NCT05929222 | Follicular Lymp... | Radiotherapy Radiotherapy pl... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00335140 | Lymphoma | Rituximab Cytarabine Dexamethasone Leucovorin Methotrexate Procarbazine Vincristine | 18 Years - | Eastern Cooperative Oncology Group | |
| Exercise Program for Adolescents and Young Adults With Cancer | NCT00502749 | Leukemia Lymphoma | Exercise progra... Questionnaires | 12 Years - 25 Years | M.D. Anderson Cancer Center | |
| Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer | NCT00312429 | Hematologic Neo... | Stem Cell Trans... | 18 Years - 70 Years | Duke University | |
| Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease | NCT00129753 | Hodgkin's Disea... Lymphoma | Alemtuzumab (Ca... | 18 Years - | M.D. Anderson Cancer Center | |
| Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | NCT00070083 | Lymphoma | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 19 Years - | National Cancer Institute (NCI) | |
| A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor | NCT03235544 | Lymphoma | Parsaclisib | 18 Years - | Incyte Corporation | |
| Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma | NCT00101010 | Lymphoma | Filgrastim Pegfilgrastim Rituximab Cyclophosphamid... Pegylated lipos... Prednisone Vincristine Sul... | 61 Years - | M.D. Anderson Cancer Center | |
| Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | NCT02062632 | Esophageal Carc... Hypopharyngeal ... Laryngeal Carci... Lymphoma Mesothelioma Metastatic Mali... Metastatic Mali... Metastatic Mali... Non-Small Cell ... Sarcoma Small Cell Lung... Thymic Carcinom... Thymoma Thyroid Gland C... | Doxepin Hydroch... Placebo Quality-of-Life... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma | NCT00907036 | Lymphoma | alemtuzumab donor lymphocyt... cyclosporine fludarabine pho... melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | NCT00451178 | Lymphoma | enzastaurin rituximab cyclophosphamid... doxorubicin vincristine prednisone | 18 Years - | Eli Lilly and Company | |
| Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia | NCT00324779 | Leukemia Lymphoma | rituximab | - 18 Years | National Cancer Institute (NCI) | |
| Treatment of Disseminated High Grade Lymphoma | NCT00536393 | Lymphoma | Doxorubicin Doxorubicin peg... | 60 Years - 75 Years | French Innovative Leukemia Organisation | |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | NCT01846429 | Tumor Cancer Pain Malignant Solid... Unresectable Ma... Hematologic Mal... Multiple Myelom... Lymphoma Neoplasm Metast... | Sodium Bicarbon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma | NCT00070447 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... yttrium Y 90 ib... | 18 Years - | National Cancer Institute (NCI) | |
| Effect of Needle Size in Diagnostic Yield of EBUS-TBNA in Sarcoidosis and Lymphoma | NCT03573362 | Sarcoidosis Lymphoma Adenopathy Hila... | ViziShot FLEX 1... Vizishot 22G ne... | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 | NCT04746092 | CLL Multiple Myelom... Lymphoma | 18 Years - 100 Years | Tel-Aviv Sourasky Medical Center | ||
| A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). | NCT01021358 | Lymphoma Chronic Lymphoc... Solid Tumors | ABT-263 Ketoconazole | 18 Years - | Abbott | |
| Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | NCT00040690 | Leukemia Lymphoma | filgrastim cyclophosphamid... cytarabine doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate vincristine sul... radiation thera... | 16 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | NCT00026208 | Lymphoma, Hodgk... Lymphoma Hodgkin Disease Lymphoma: Hodgk... | Vincristine Cyclophosphamid... Doxorubicin Prednisone Bleomycin Etoposide Low-dose radiot... | 18 Years - 70 Years | Stanford University | |
| Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | NCT00795132 | Acute Leukaemia Chronic Disease Leukemia Myelodysplasia Lymphoma | Busulfan Anti-Thymocyte ... Fludarabine Cyclosporine Mycophenolate m... | - 21 Years | University of Utah | |
| Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer | NCT00002742 | Chronic Myelopr... Infection Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | amphotericin B ... nystatin | 2 Years - | National Cancer Institute (NCI) | |
| Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma | NCT00689169 | Lymphoma, Large... | ZBEAM (Zevalin,... ASCT Rituximab | 18 Years - 65 Years | Lymphoma Study Association | |
| Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | NCT03465891 | Lymphoma | atezolizumab Low- Dose, Loca... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Rituximab in Treating Patients With Hodgkin's Lymphoma | NCT00003820 | Lymphoma Hodgkin Lymphom... Nodular Lymphoc... | Rituximab | 3 Years - | Stanford University | |
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment | NCT02099266 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Hodgkins Lympho... Non-Hodgkins Ly... | Administration ... | 17 Years - 70 Years | University of Kansas Medical Center | |
| Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease | NCT00004010 | Lymphoma | bleomycin sulfa... filgrastim ABVD regimen cyclophosphamid... dacarbazine doxorubicin hyd... etoposide prednisone procarbazine hy... vinblastine sul... vincristine sul... radiation thera... | - 21 Years | Children's Oncology Group | |
| Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | NCT05751798 | Solid Advanced ... Lymphoma | OSE-279 100mg OSE-279 300mg OSE-279 500mg | 18 Years - | OSE Immunotherapeutics | |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | NCT00723099 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg... | Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... | - 69 Years | Fred Hutchinson Cancer Center | |
| Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00081861 | Lymphoma | Avastin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | NCT00055640 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... microarray anal... | 18 Years - | Case Comprehensive Cancer Center | |
| Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | NCT00003639 | Lymphoma | recombinant int... chlorambucil dexamethasone idarubicin | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation | NCT02905942 | Lymphoma | PEG-rhG-CSF rhG-CSF | 18 Years - 65 Years | Peking University | |
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation | NCT00003056 | Leukemia Lymphoma Graft Versus Ho... | cyclosporine cyclosporine an... | 18 Years - 55 Years | Takeda | |
| Danish Elder Lymphoma Patient Hematopoietic Investigation | NCT05245487 | Lymphoma Chemotherapy-in... Chemotherapy-Re... Chemotherapeuti... | DNA repair gene... | 60 Years - | Rigshospitalet, Denmark | |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | NCT00546377 | Leukemia Lymphoma | filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| UPLYFT For Lymphoma Survivors | NCT05080166 | Lymphoma Survivorship | Interview with ... Field Test of U... Pilot of UPLYFT... | 18 Years - | Dana-Farber Cancer Institute | |
| Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) | NCT00368082 | Lymphoma Hodgkin's Disea... Relapse Lymphoma, Non-H... | TGFbeta resista... | - | Baylor College of Medicine | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00262860 | Lymphoma | bortezomib gemcitabine hyd... | 18 Years - 120 Years | University of Rochester | |
| LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) | NCT04446962 | Lymphoma, Large... Central Nervous... | Lenalidomide Ibrutinib | 18 Years - 65 Years | Institut Curie | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma | NCT00634452 | Hodgkin's Lymph... | MDX-1401 | 12 Years - | Bristol-Myers Squibb | |
| Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma | NCT00561301 | Lymphoma | GemDOx | 15 Years - 65 Years | Cooperative Study Group A for Hematology | |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
| Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation | NCT00003143 | Lymphoma | Amifostine DHAP | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation | NCT06328699 | Lymphoma Multiple Myelom... | Spiritual Thera... Best Practice | 18 Years - | Emory University | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma | NCT00796731 | Lymphoma Non-Hodgkin | SAR3419 | 18 Years - | Sanofi | |
| Bone Marrow Transplantation in Treating Patients With Lymphoma | NCT00002829 | Lymphoma | Recombinant Int... Cyclophosphamid... Etoposide Mesna Bone Marrow Tra... Radiation Thera... | 15 Years - 60 Years | M.D. Anderson Cancer Center | |
| Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy | NCT03144583 | Leukemia Lymphoma | Adult different... | 2 Years - 80 Years | Institut d'Investigacions Biomèdiques August Pi i Sunyer | |
| Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma | NCT03468153 | Lymphoma | Dual Specificit... | 18 Years - 65 Years | Ruijin Hospital | |
| A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma | NCT04837222 | Lymphoma | No Intervention | 18 Years - | Takeda | |
| Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | NCT02974647 | Lymphoma | Ruxolitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors | NCT05156203 | Advanced Solid ... Lymphoma | T-1301 Capsules | 20 Years - | Taivex Therapeutics Corporation | |
| Beta Alethine in Treating Patients With Low-Grade Lymphoma | NCT00007839 | Lymphoma | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) | NCT00500240 | Leukemia Lymphoma | Insulin Glargin... Insulin Aspart | 15 Years - | M.D. Anderson Cancer Center | |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | NCT01263418 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, B-Cel... Lymphoma, Low-G... Lymphoma, Inter... | Ofatumumab | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma | NCT00003280 | Lymphoma | rituximab | 18 Years - 120 Years | Swiss Group for Clinical Cancer Research | |
| Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies | NCT03262298 | Leukemia Lymphoma | Anti-CD22-CAR-t... | 18 Years - 65 Years | Affiliated Hospital to Academy of Military Medical Sciences | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies | NCT01943851 | Neoplasms | GSK525762 | 18 Years - | GlaxoSmithKline | |
| Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma | NCT02724904 | Lymphoma | Allogeneic stem... Fludarabine Thiotepa Methotrexate | 18 Years - | Massachusetts General Hospital | |
| Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | NCT00032019 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... etoposide prednisone vincristine sul... | - | Alliance for Clinical Trials in Oncology | |
| Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00290004 | Chronic Lymphoc... Small Lymphocyt... Leukemia Lymphoma | motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma | NCT05873322 | Precursor Cell ... Drug-Induced Di... Impaired Glucos... Lymphoma | 1 Year - 17 Years | Aarhus University Hospital | ||
| Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation | NCT00889278 | Lymphoma | 18 Years - | Dartmouth-Hitchcock Medical Center | ||
| Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) | NCT03098589 | Lymphoma | Revlimid | 18 Years - | Celgene | |
| Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides | NCT00002557 | Lymphoma | CHOP regimen doxorubicin hyd... etoposide leucovorin calc... methotrexate | - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
